Masimo Corporation (MASI)

In the past six months, Masimo Corp. experienced several significant stock-impacting events. On November 14, 2025, a California jury found Apple liable for patent infringement and awarded Masimo $634 million in damages. On December 3, 2025, Masimo hosted its 2025 Investor Day, outlining a strategic roadmap for growth and financial targets. On January 12, 2026, Masimo announced preliminary financial results for Q4 and the full year ended January 3, 2026. On February 17, 2026, Danaher Corporation announced an agreement to acquire Masimo for $180.00 per share. On February 26, 2026, Masimo reported its complete fourth quarter and full year 2025 financial results. On March 20, 2026, news highlighted a study finding that respiratory changes often precede patient decline.

Masimo's products and services experience some demand seasonality. Healthcare revenues in the third quarter tend to be lower due to summer vacation schedules in the U.S., European, and Japanese markets. The stock has historically shown its strongest performance in November, while May tends to be the weakest month. The timing and severity of flu seasons can also impact demand.

Masimo Corporation is a global medical technology and consumer electronics company based in Irvine, California. It operates primarily in the healthcare sector, focusing on medical devices and equipment, and also has a presence in the consumer audio and wearables market. Masimo is known for its noninvasive patient monitoring technologies, including Masimo SET® pulse oximetry, and its product portfolio includes advanced Rainbow Pulse CO-Oximetry parameters, SedLine brain function monitoring, and Capnography and gas monitoring. Additionally, Masimo develops home sound integration technologies and licenses in-vehicle audio systems under brands like Bowers & Wilkins, Denon, and Marantz.

Masimo Corporation has a significant global presence with operations and distribution networks across the Americas, Europe, Asia, the Middle East, Africa, and Australia. The United States is its largest healthcare revenue source, driven by IDNs, academic medical centers, and hospital-at-home initiatives. North America and Western Europe are key markets with high adoption rates, and the company is expanding in Asia-Pacific and emerging markets.

In the past year, Masimo's brand reputation has been positively influenced by several events. On April 22, 2025, Masimo's 2024 Sustainability Report highlighted the positive impact of redesigned sensors and packaging. On June 10, 2025, Vanderbilt University Medical Center began piloting the integration of Masimo Radius VSM™ in its proactive care protocol. On November 14, 2025, a California jury's verdict finding Apple liable for patent infringement bolstered Masimo's reputation. On November 20, 2025, Masimo emphasized its commitment to patient safety through initiatives. On March 19, 2026, Masimo co-sponsored the CFSI/Masimo Excellence in Fire Service-Based EMS Award.

Masimo's ownership is largely concentrated among institutional holders, including Vanguard Group (approximately 11.2%), BlackRock, Inc. (roughly 9.4%), State Street Corporation, and FMR LLC (Fidelity), which collectively hold over 15%. Politan Capital Management (Quentin Koffey) has a significant stake of approximately 9%. Joe Kiani, the company's founder, maintains a notable individual stake.